- Fee assured
- Verified this account
This healthcare professional is currently treating patients. Please speak to them to find out more about their availability.
Last updated: 12 Nov 2020
- Video and telephone consultations
Dr Bartlett was appointed as a Consultant Clinical Oncologist at Portsmouth Hospitals NHS Trust in 2015. He is also a visiting Consultant at St Richard’s Hospital, Chichester.
Dr Bartlett specialises in the treatment of breast and upper gastrointestinal cancers. He trained in London and the South of England and subsequently undertook a research degree into heart-sparing breast radiotherapy techniques at the Royal Marsden Hospital and the Institute of Cancer Research. He has published and spoken extensively on this subject and his work has changed UK breast radiotherapy practice.
He retains an active research interest and is a Principal Investigator for the NeoAEGIS and SCOPE 2 clinical trials.
Dr Bartlett also has a particular interest in diet and its role in cancer prevention and treatment and is the Clinical Lead for Cancer Prevention at the Wessex Cancer Alliance.
Areas of interest
Breast cancer; stomach cancer; oesophagus cancer; pancreas cancer; gallbladder cancer; cholangiocarcinoma; chemotherapy; radiotherapy; IMRT; IGRT
- JoVE publication on Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Current NHS consultant posts held
Consultant Clinical Oncologist, Queen Alexandra Hospital (Portsmouth) and St Richard's Hospital (Chichester)
Heart-sparing breast radiotherapy
Neoadjuvant and definitive chemoradiotherapy for oesophagus cancer
Family; sailing; food and wine; squash; cycling.
Royal College of Radiologists Frank EIllis Medal (2017) for the paper published in Clinical Oncology considered to have made the best contribution to advancing the cause of science in cancer treatment.
Institute of Cancer Research Chairman’s Prize for the outstanding graduating MD(Res) Student (2016).
Finalist in QiC Excellence in Oncology Awards (Cancer Team Of The Year 2013).
Royal College of Radiologists Ross Prize for best oral presentation (NCRI Conference, Liverpool 2012).
Evaluation of a Novel Field-placement Algorithm for Locoregional Breast Cancer Radiotherapy Including the Internal Mammary Chain. Ranger A, Dunlop A, Shah P, Amin, K, Henderson D, Bartlet FR, Knowles C, Brigden B, Lacey C, Donovan E, Harris E, Kirby AM. Clin Oncol (R Coll Radiol) 2019; 31: 25-33.
A cardiac contouring atlas for radiotherapy. Duane F, Aznar MC, Bartlett F, Cutter DJ, Darby SC, Jagsi R, Lorenzen EL, McArdle O, McGale P, Myerson S, Rahimi K, Vivekanandan S, Warren S, Taylor CW. Radiother Oncol 2017; 122(3): 416–422.
The UK HeartSpare Study (Stage II): Multicentre evaluation of a voluntary breath-hold technique in patients receiving breast radiotherapy. Bartlett FR, Donovan EM, McNair HA, Corsini LA, Colgan RM, Evans PM, Maynard L, Griffin C, Haviland JS, Yarnol JR, Kirby AM. Clin Oncol (R Coll Radiol) 2017; 29(3): e51-e56.
A randomized control trial evaluating fluorescent ink versus dark ink tattoos for breast radiotherapy. Landeg SJ, Kirby AM, Lee SF, Bartlett F, Titmarsh K, Donovan E, Griffin CL, Gothard L, Locke I, McNair HA. Br J Radiol 2016; 89(1068): 20160288.
Mean heart dose variation over a course of breath holding breast cancer radiotherapy. Dunkerley N, Bartlett FR, Kirby AM, Evans PM, Donovan EM. Br J Radiol 2016; 89(1067): 20160536.
Voluntary breath-holding for breast cancer radiotherapy is consistent and stable. Colgan R, James M, Bartlett FR, Kirby AM, Donovan EM. Br J Radiol 2015; 88(1054): 20150309.
The UK HeartSpare Study (Stage IB): Randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Bartlett FR, Colgan RM, Donovan EM, McNair HA, Carr K, Evans PM, Griffin C, Locke I, Haviland JS, Yarnold JR, Kirby AM. Radiother Oncol 2015; 114(1): 66-72.
Voluntary breath-hold technique for reducing heart dose in left breast radiotherapy. Bartlett FR et al. J Vis Exp 2014: e51578.
The UK HeartSpare study. Bartlett FR, Kirby AM. RAD Magazine 2014; 40(464):30-31.
Breast Radiotherapy and Heart Disease – Where Are We Now? Bartlett FR et al. Clin Oncol (R Coll Radiol) 2013; 25(12): 687-689.
Multileaf Collimation Cardiac Shielding in Breast Radiotherapy: Cardiac Doses are Reduced, But at What Cost? Bartlett FR et al. Clin Oncol (R Coll Radiol) 2013; 25(12): 690-696.
The UK HeartSpare Study: Randomised evaluation of voluntary deep-inspiratory breath-hold in women undergoing breast radiotherapy.
Bartlett FR et al. Radiother Oncol 2013; 108(2): 242-247.
- MD (Res) Institute of Cancer Research, London 2015
- FRCR Royal College of Radiologists 2010
- MRCP Royal College of Physicians 2006
- MB BS (Lond) Imperial College School of Medicine, London 2003
- BSc in Neurosciences and Basic Biomedical Sciences Imperial College School of Medicine, London 2001
Reference number 6078381
Details of entry to specialist register
- Consultant Clinical Oncologist, 2015
Affiliations / memberships
Member of the Royal College of Radiologists
- GenesisCare Portsmouth
- 10:30 - 14:30
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Spire Portsmouth Oncology Patient Helpline: + 44 7525 275950.
Acute Oncology Service, QAH - 02392 28600 Ext 3316